Friday, November 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 6, 2026

Mobileye To Acquire Mentee Robotics to Accelerate Physical AI Leadership

View original at finance.yahoo.com
Mobileye To Acquire Mentee Robotics to Accelerate Physical AI Leadership Mobileye and Mentee RoboticsMentee Robotics is developing an AI-first, vertically integrated humanoid robot designed for real-world usefulness and adaptability.MenteeBot showcases the complete autonomous execution of a task, encompassing scene per…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Joining forces with Mobileye gives access to unparalleled AI infrastructure and commercialization expertise, accelerating mission to bring scalable, safe, and cost-effective humanoid solutions to market

    80% confidence
  • Mentee's multidisciplinary team accomplished building a platform that combines cutting-edge AI with deeply integrated hardware to make humanoid robots truly useful in real-world environments in just four years

    80% confidence
  • Strong traction in advanced vehicle autonomy and core ADAS technology has resulted in current automotive revenue pipeline of $24.5 billion over next eight years, up more than 40 percent compared to January 2023

    80% confidence
  • By combining Mentee's breakthroughs in humanoid robotics with Mobileye's expertise in automotive autonomy, and its proven ability to productize advanced AI, we have a unique opportunity to lead the evolution of physical AI across robotics and autonomous vehicles on a global scale

    80% confidence
  • Today marks a new chapter for robotics and automotive AI, and the beginning of Mobileye 3.0

    80% confidence
  • Transaction expected to modestly increase Mobileye's operating expenses in 2026 by a low-single-digit percentage

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com